Europe, Middle East, and Africa Point-of-Care Diagnostics Market Size, Share & Trends Analysis Report By Product (Blood Gas, Infectious Diseases, Hospital Glucose Testing, Cardiac Markers, Hematology, Coagulation, Primary Care Systems, Decentralized Clinical Chemistry, Urinalysis, Drug Abuse Testing) And Segment Forecasts To 2022
- Report ID: 978-1-68038-806-0
- Number of Pages: 174
- Format: Electronic (PDF)
- Historical Data: 2013-2015
- Industry: Healthcare
Market segmentation
- EMEA Point-of-Care Diagnostics Market Product Outlook (Revenue, USD Million, 2015 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Glucose testing
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- EMEA Point-of-Care Diagnostics Market End-use Outlook (Revenue, USD Million, 2015 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- EMEA Point-of-Care Diagnostics Market Regional Outlook(Revenue, USD Million, 2015 - 2022)
- Europe
- Germany
- Germany Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Germany End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Benelux Union
- Belgium
- Belgium Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Belgium End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Netherlands
- Netherlands Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Netherlands End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Luxembourg
- Luxembourg Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Luxembourg End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- France
- France Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- France End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Spain
- Spain Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Spain End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Portugal
- Portugal Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Portugal End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Italy
- Italy Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Italy End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Scandinavia
- Denmark
- Denmark Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Denmark End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Norway
- Norway Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Norway End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Sweden
- Sweden Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Sweden End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Finland
- Finland Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Finland End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- UK
- UK Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- UK End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Turkey
- Turkey Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Turkey End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Rest of Europe
- Rest of Europe Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Rest of Europe End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Germany
- MEA
- South Africa
- South Africa Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- South Africa End-Use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Nigeria
- Nigeria Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Nigeria End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Kenya
- Kenya Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Kenya End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Zimbabwe
- Zimbabwe Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Zimbabwe End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Saudi Arabia
- Saudi Arabia Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Saudi Arabia End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- United Arab Emirates
- United Arab Emirates Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- United Arab Emirates End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Qatar
- Qatar Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Qatar End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- Rest of MEA
- Rest of MEA Product Outlook (Revenue, USD Million, 2012 - 2022)
- Glucose testing
- Over The Counter (OTC)
- Prescribed
- Cardiac markers
- Fertility
- Blood gas and electrolytes
- Decentralized clinical chemistry
- Infectious disease testing
- Coagulation
- Over The Counter (OTC)
- Prescribed
- Primary care systems
- Hematology
- Urinalysis
- Drug abuse testing
- Others
- Rest of MEA End-use Outlook (Revenue, USD Million, 2012 - 2022)
- Hospitals
- Clinics
- Laboratories
- Assisted living healthcare facilities
- Others
- South Africa
- Europe
Report Content
Qualitative Analysis
- Industry overview
- Industry trends
- Market drivers and restraints
- Market size
- Growth prospects
- Porter’s analysis
- PESTEL analysis
- Key market opportunities prioritized
- Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments
Quantitative Analysis
- Market size, estimates, and forecast from 2012 to 2022
- Revenue estimates for product up to 2022
- Revenue estimates for end-use up to 2022
- Regional market size and forecast for product up to 2022
- Regional market size and forecast for end-use up to 2022
- Company financial performance
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
